Reported 1 day ago
Eli Lilly announced plans to acquire Scorpion Therapeutics' experimental oral cancer therapy, STX-478, for up to $2.5 billion. The therapy, targeting a specific protein related to breast cancer and advanced tumors, is currently in early-stage trials. The acquisition includes an upfront payment and contingent payments based on regulatory and sales milestones, while Scorpion will create a new entity to manage its non-PI3K assets.
Source: YAHOO